First proof of bismuth oxide nanoparticles as efficient radiosensitisers on highly radioresistant cancer cells.

Citation data:

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB), ISSN: 1724-191X, Vol: 32, Issue: 11, Page: 1444-1452

Publication Year:
Usage 40
Abstract Views 21
Downloads 19
Captures 23
Readers 23
Social Media 1
Tweets 1
Citations 7
Citation Indexes 7
Repository URL:
Stewart, Callum; Konstantinov, Konstantin K; McKinnon, Sally; Guatelli, Susanna; Lerch, Michael L. F; Rosenfeld, Anatoly B; Tehei, Moeava; Corde, Stephanie
Elsevier BV
Biochemistry, Genetics and Molecular Biology; Medicine; Physics and Astronomy; first; oxide; proof; cancer; cells; nanoparticles; efficient; radiosensitisers; highly; bismuth; radioresistant; Medicine and Health Sciences
Most Recent Tweet View All Tweets
article description
This study provides the first proof of the novel application of bismuth oxide as a radiosensitiser. It was shown that on the highly radioresistant 9L gliosarcoma cell line, bismuth oxide nanoparticles sensitise to both kilovoltage (kVp) or megavoltage (MV) X-rays radiation. 9L cells were exposed to a concentration of 50μg.mL of nanoparticle before irradiation at 125kVp and 10MV. Sensitisation enhancement ratios of 1.48 and 1.25 for 125kVp and 10MV were obtained in vitro, respectively. The radiation enhancement of the nanoparticles is postulated to be a combination of the high Z nature of the bismuth (Z=83), and the surface chemistry. Monte Carlo simulations were performed to elucidate the physical interactions between the incident radiation and the nanoparticle. The results of this work show that BiO nanoparticles increase the radiosensitivity of 9L gliosarcoma tumour cells for both kVp and MV energies. Monte Carlo simulations demonstrate the advantage of a platelet morphology.